Transvaginal Mesh Patches
Transvaginal mesh patches have been linked to serious complications. The FDA has received more than 3,800 reports of adverse effects caused after or during implantation of the surgical mesh.
About Transvaginal Mesh
Transvaginal mesh patches are surgically implanted to combat the effects of pelvic organ prolapse (POP) and stress urinary incontinence (SUI). POP occurs when the pelvic muscles weaken, causing the pelvic organs to descend from their normal place and bulge through the vaginal wall. The popularity of surgically implanting transvaginal mesh patches to hold organs in place has increased since the device’s 2001 approval, but unfortunately, the patch has been linked to painful and serious complications.
As reported by the FDA, significant problems resulting from the use of transvaginal mesh may include:
- Erosion of the vaginal tissue
- Urinary problems such as incontinence
- Pain during sexual intercourse (dyspareunia)
- Organ perforation (puncturing) from surgical tools during mesh implantation
- Return of POP
- Neuro-muscular problems
- Vaginal scarring/shrinkage
- Emotional problems
Research Indicates the Patch’s Serious Risks
In May 2011, a study published in the New England Journal of Medicine indicated the dangers associated with the use of the transvaginal mesh patch. Researchers found that the patch when compared to colporrhaphy, the traditional method of stitching vaginal wall tissues together, the mesh patch had a higher risk of harm or defect including:
- 7 times the risk of bladder perforation
- Double the risk of urinary incontinence (loss of bladder control)
- 3.2 percent of women required revision surgery to correct exposure problems
In 2010, a study featured in the Obstetrics & Gynecology journal had to be terminated due to the extent of surgical mesh-related injuries. Of the women who received the transvaginal mesh implant, 15 percent experienced erosions, and other complications included two cystotomies (bladder incisions) and one blood transfusion.
FDA Transvaginal Mesh Patches Safety Alerts
FDA Alert, 2011 – This FDA announcement warned of the serious complications associated with the transvaginal placement of surgical mesh. Additionally, the FDA made an important note that surgical mesh treatment of POP is no more effective than the traditional method, in addition to being riskier.
The FDA received more than 2,874 reports between 2008 and 2010 of adverse complications caused by the transvaginal mesh patch method of repairing POP. This brings the total number of adverse reports to more than 3,800 since 2005.
If you experienced complications after receiving the transvaginal mesh patch, you may be eligible for compensation to ease the financial burdens associated with your injury, as well as offset your physical and emotional pain and suffering. Contact us today to set up a free consultation, during which we will listen to your story, answer any questions you may have and discuss your legal rights and options. If you choose us to represent you, we will work with you on a contingency fee basis; this means you pay nothing until we have secured compensation for you, either through a jury verdict or settlement.